Diabetes tech companies continue 2020's success with Q1 growth. Investors seem unimpressed.

Dexcom, Insulet and Tandem all grew revenue or sales in Q1, winning over Wall Street analysts but seemingly not investors. Meanwhile, the diabetes tech space grows with Bigfoot Biomedical clearance.